These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 38789373)

  • 21. Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination.
    Gorochov G; Ropers J; Launay O; Dorgham K; da Mata-Jardin O; Lebbah S; Durier C; Bauer R; Radenne A; Desaint C; Vieillard LV; Rekacewicz C; Lachatre M; Parfait B; Batteux F; Hupé P; Ninove L; Lefebvre M; Conrad A; Dussol B; Maakaroun-Vermesse Z; Melica G; Nicolas JF; Verdon R; Kiladjian JJ; Loubet P; Schmidt-Mutter C; Dualé C; Ansart S; Botelho-Nevers E; Lelièvre JD; de Lamballerie X; Kieny MP; Tartour E; Paul S
    JAMA Netw Open; 2024 Apr; 7(4):e248051. PubMed ID: 38652471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and antibody response of the BNT162b2 SARS-CoV-2 vaccine in children aged 5-11 years with underlying diseases: A prospective observational study.
    Funaki T; Yamada M; Miyake K; Ueno S; Myojin S; Aiba H; Matsui T; Ogimi C; Kato H; Miyairi I; Shoji K
    J Infect Chemother; 2024 Aug; 30(8):773-779. PubMed ID: 38387787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia.
    Merid Y; Tekleselasie W; Tesfaye E; Gadisa A; Fentahun D; Abate A; Alemu A; Mihret A; Mulu A; Gelanew T
    Front Immunol; 2023; 14():1163688. PubMed ID: 37398668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV-POPART cohort participants.
    Chalouni M; Loubet P; Lhomme E; Ninove L; Barrou B; Blay JY; Hourmant M; de Seze J; Laville M; Laviolle B; Lelièvre JD; Morel J; Quoc SN; Spano JP; Terrier B; Thiebaut A; Viallard JF; Vrtovsnik F; Circosta S; Barquin A; Gharib M; Tartour E; Parfait B; Thiébaut R; Meyer L; de Lamballerie X; Launay O; Wittkop L;
    BMC Infect Dis; 2024 Sep; 24(1):1049. PubMed ID: 39333909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PMMA dialyzers modulate both humoral and cell-mediate immune response to anti-COVID-19 vaccine (BNT162b2) in a cohort of chronic hemodialyzed patients.
    Castellano G; Netti GS; Cantaluppi V; Losappio V; Spadaccino F; Ranieri E; Marengo M; Borzumati M; Alfieri C; Stallone G
    Sci Rep; 2024 May; 14(1):12217. PubMed ID: 38806543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Booster vaccination using bivalent DS-5670a/b is safe and immunogenic against SARS-CoV-2 variants in children aged 5-11 years: a phase 2/3, randomized, active-controlled study.
    Suzuki R; Suda M; Ishida K; Furihata K; Ota A; Takahashi K; Sakakibara S; Nakayama T; Takeshita F
    Front Immunol; 2024; 15():1445459. PubMed ID: 39286253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response.
    Mileto D; Fenizia C; Cutrera M; Gagliardi G; Gigantiello A; De Silvestri A; Rizzo A; Mancon A; Bianchi M; De Poli F; Cuomo M; Burgo I; Longo M; Rimoldi SG; Pagani C; Grosso S; Micheli V; Rizzardini G; Grande R; Biasin M; Gismondo MR; Lombardi A
    Emerg Microbes Infect; 2021 Dec; 10(1):2235-2243. PubMed ID: 34749573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of past infection with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers: Kinetics and durability of the humoral immune response.
    Ontañón J; Blas J; de Cabo C; Santos C; Ruiz-Escribano E; García A; Marín L; Sáez L; Beato JL; Rada R; Navarro L; Sainz de Baranda C; Solera J
    EBioMedicine; 2021 Nov; 73():103656. PubMed ID: 34740112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
    Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
    Front Immunol; 2021; 12():690698. PubMed ID: 34276681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
    Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G
    Front Immunol; 2021; 12():737083. PubMed ID: 34539673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
    Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
    Front Immunol; 2021; 12():704773. PubMed ID: 34220867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Altered transcriptomic immune responses of maintenance hemodialysis patients to the COVID-19 mRNA vaccine.
    Chang YS; Huang K; Lee JM; Vagts CL; Ascoli C; Amin MR; Ghassemi M; Lora CM; Edafetanure-Ibeh R; Huang Y; Cherian RA; Sarup N; Warpecha SR; Hwang S; Goel R; Turturice BA; Schott C; Hernandez M; Chen Y; Jorgensen J; Wang W; Rasic M; Novak RM; Finn PW; Perkins DL
    Elife; 2024 Apr; 13():. PubMed ID: 38656290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BNT162b2 versus mRNA-1273 Third Dose COVID-19 Vaccine in Patients with CKD and Maintenance Dialysis Patients.
    Yau K; Tam P; Chan CT; Hu Q; Qi F; Abe KT; Kurtesi A; Jiang Y; Estrada-Codecido J; Brown T; Liu L; Siwakoti A; Leis JA; Levin A; Oliver MJ; Colwill K; Gingras AC; Hladunewich MA
    Clin J Am Soc Nephrol; 2024 Jan; 19(1):85-97. PubMed ID: 37847518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People.
    Demaret J; Corroyer-Simovic B; Alidjinou EK; Goffard A; Trauet J; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Labreuche J; Sobaszek A; Hisbergues M; Puisieux F; Labalette M; Lefèvre G
    Front Immunol; 2021; 12():778679. PubMed ID: 34868051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of previous COVID-19 exposure and vaccine type (CoronaVac, ChAdOx1 nCov-19 or BNT162b2) on antibody and cytokine (Th1 or Th2) responses.
    Padilla-Bórquez DL; Matuz-Flores MG; Hernández-Bello J; Rosas-Rodríguez JA; Turrubiates-Hernández FJ; García-Arellano S; González-Estevez G; Ceja-Galvez HR; Oregon-Romero E; López-Reyes A; Muñoz-Valle JF
    Hum Vaccin Immunother; 2024 Dec; 20(1):2394265. PubMed ID: 39246041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection.
    Gobbi F; Buonfrate D; Moro L; Rodari P; Piubelli C; Caldrer S; Riccetti S; Sinigaglia A; Barzon L
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33807957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of the induction of humoral and cellular immunity by third vaccination for SARS-CoV-2.
    Murayama G; Kusaoi M; Horiuchi Y; Tabe Y; Naito T; Ito S; Yamaji K; Tamura N
    J Infect Chemother; 2024 Oct; 30(10):1021-1027. PubMed ID: 38570139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential Dynamics of SARS-CoV-2 Binding and Functional Antibodies upon BNT162b2 Vaccine: A 6-Month Follow-Up.
    Matusali G; Sberna G; Meschi S; Gramigna G; Colavita F; Lapa D; Francalancia M; Bettini A; Capobianchi MR; Puro V; Castilletti C; Vaia F; Bordi L
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Impact of Time between Booster Doses on Humoral Immune Response in Solid Organ Transplant Recipients Vaccinated with BNT162b2 Vaccines.
    Hamm SR; Loft JA; Pérez-Alós L; Heftdal LD; Hansen CB; Møller DL; Pries-Heje MM; Hasselbalch RB; Fogh K; Hald A; Ostrowski SR; Frikke-Schmidt R; Sørensen E; Hilsted L; Bundgaard H; Garred P; Iversen K; Perch M; Sørensen SS; Rasmussen A; Sabin CA; Nielsen SD
    Viruses; 2024 May; 16(6):. PubMed ID: 38932153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19.
    Lozano-Rodríguez R; Valentín-Quiroga J; Avendaño-Ortiz J; Martín-Quirós A; Pascual-Iglesias A; Terrón-Arcos V; Montalbán-Hernández K; Casalvilla-Dueñas JC; Bergón-Gutiérrez M; Alcamí J; García-Pérez J; Cascajero A; García-Garrido MÁ; Balzo-Castillo ÁD; Peinado M; Gómez L; Llorente-Fernández I; Martín-Miguel G; Herrero-Benito C; Benito JM; Rallón N; Vela-Olmo C; López-Morejón L; Cubillos-Zapata C; Aguirre LA; Fresno CD; López-Collazo E
    Cell Rep; 2022 Jan; 38(2):110235. PubMed ID: 34986327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.